Ralf C. Bargou

Ralf Bargou is a pioneer in T cell-engaging bispecific antibody therapy who led the clinical development of blinatumomab (Blincyto), the first FDA-approved BiTE (bispecific T cell engager) antibody. His work demonstrated that redirecting T cells using bispecific antibodies could achieve remarkable responses in patients with refractory B-cell malignancies, establishing a new class of cancer immunotherapy.

Ralf Bargou是T细胞结合双特异性抗体治疗的先驱，领导了blinatumomab（Blincyto）的临床开发，这是首个FDA批准的BiTE（双特异性T细胞结合器）抗体。他的工作表明，使用双特异性抗体重定向T细胞可以在难治性B细胞恶性肿瘤患者中实现显著反应，建立了一类新的癌症免疫治疗。